Akums Drugs & Pharmaceuticals (AKUMS) Share Price Falls in Second Straight Session
- October 9, 2026
- Posted by: Kunal Singla
- Category: News
Akums Drugs & Pharmaceuticals Share Price Fall Streak is extending in its second straight session, with the latest traded price at Rs 744.5 after a 5.27% decline today. Univest figures confirm the price action, but they do not point to a specific company trigger. The cumulative move across the streak stands at -9.44% from the streak start base price of Rs 822.1, keeping Akums Drugs & Pharmaceuticals in focus for a sharper share price fall than a one-off move.
The company’s market capitalisation stands at Rs 12,939.36 crore, which places it in the Mid Cap category. For a reader tracking Akums Drugs & Pharmaceuticals Share Price Fall Streak, the relevance is not only the lower quote but the fact that two lower sessions in a row change the way the move is read versus a single-day decline. Univest data shows the pattern clearly, while the broader interpretation still needs to come from the price action, valuation and sector context below.
Akums Drugs & Pharmaceuticals (AKUMS) Share Price Fall Streak: Consecutive Decline Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 744.5 |
| Previous Close | Rs 785.95 |
| Today's Move | -Rs 41.45 (-5.27%) |
| Open | Rs 783.35 |
| High | Rs 790 |
| Low | Rs 740.75 |
| Market Capitalisation | Rs 12,939.36 crore |
Akums Drugs & Pharmaceuticals share price today was lower at Rs 744.5 versus the previous close of Rs 785.95, a difference of Rs 41.45 or 5.27%. The stock opened at Rs 783.35, touched a high of Rs 790 and a low of Rs 740.75, and the latest trade sat much closer to the day’s low than the day’s high. That range matters because it shows where the share price spent the session after the open.
Market capitalisation stood at Rs 12,939.36 crore, and the Mid Cap label is the right company-size context here. In Akums Drugs & Pharmaceuticals Share Price Fall Streak terms, the move is not just about the current quote; it is also about how the latest trade behaved inside the session range and how the second straight session of weakness changed the near-term read. Akums Drugs & Pharmaceuticals share price today therefore needs to be viewed as a continuation of the fall pattern, not as an isolated intraday dip. That brings the fundamental analysis into sharper focus.
What the Consecutive Declines Show
Akums Drugs & Pharmaceuticals Share Price Fall Streak now covers a second straight session and a cumulative decline of 9.44% from Rs 822.1. That makes the pattern more important than a one-session move because the market is now looking at a lower run rather than a single-day correction. The second straight session framing also helps readers separate a routine intraday swing from a sustained two-session slide.
For Akums Drugs & Pharmaceuticals share price, the key observation is that the latest traded price is lower than both the previous close and the streak-start base price. The cumulative move is therefore the most relevant headline number in the streak lens. Univest figures confirm the price action, but they do not point to a specific company trigger. That leaves the valuation, profitability ratios and sector comparison as the next factual reference points for Akums Drugs & Pharmaceuticals stock analysis.
Akums Drugs & Pharmaceuticals (AKUMS) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 12,939.36 crore |
| P/E Ratio | 42.4x |
| P/B Ratio | 3.62x |
| ROE | 8.06% |
| ROCE | 14.77% |
| EPS | Rs 18.53 |
| Book Value Per Share | Rs 216.98 |
| Dividend Yield | 0.38% |
Akums Drugs & Pharmaceuticals (AKUMS) fundamental metrics show P/E 42.4x, P/B 3.62x, ROE 8.06%, ROCE 14.77%. Taken on their own, these numbers offer context rather than a trading signal.
Akums Drugs & Pharmaceuticals has a market capitalisation of Rs 12,939.36 crore and falls in the Mid Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 42.4x, P/B at 3.62x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 8.06% and ROCE of 14.77%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 18.53, book value per share of Rs 216.98, dividend yield of 0.38%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.28x, median ROE of 11.61%, median ROCE of 13.46%. They set out the fundamental picture and are not a rating on the stock.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 42.4x |
| Benchmark Median P/E | 31.28x |
| Benchmark Average P/E | 47.09x |
| Benchmark P/E Range | 3.56x to 678.22x |
| Company P/B Ratio | 3.62x |
| Benchmark Median P/B | 2.85x |
| Benchmark Average P/B | 4.25x |
| Company ROE | 8.06% |
| Benchmark Median ROE | 11.61% |
| Benchmark Average ROE | 10.59% |
| Company ROCE | 14.77% |
| Benchmark Median ROCE | 13.46% |
| Benchmark Average ROCE | 13.36% |
| Company Market Capitalisation | Rs 12,939.36 crore |
| Benchmark Median Market Cap | Rs 821.44 crore |
| Benchmark Average Market Cap | Rs 14,054.13 crore |
Akums Drugs & Pharmaceuticals (AKUMS) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Akums Drugs & Pharmaceuticals (AKUMS) has a P/E ratio of 42.4x, which is above the benchmark median of 31.28x, a difference of +35.55%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Akums Drugs & Pharmaceuticals (AKUMS) has a ROE of 8.06%, which is below the benchmark median of 11.61%, a difference of -30.58%. Akums Drugs & Pharmaceuticals (AKUMS) has a ROCE of 14.77%, which is above the benchmark median of 13.46%, a difference of +9.73%.
Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,27,861.41 | 34.76 | 4.86 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,54,318.9 | 85.21 | 14.11 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,79,153.26 | 81.53 | 19.81 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,15,111.94 | 24.65 | 4.13 | 19.69 | 21.39 |
| Laurus Labs | LAURUSLABS | 1,11,034.16 | 98.83 | 19.16 | 18.31 | 18.2 |
Akums Drugs & Pharmaceuticals (AKUMS) has a P/E ratio of 42.4x compared with the displayed peer median of 81.53x. The comparison is relative and should not be read as a recommendation. Its ROE of 8.06% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 14.77% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Akums Drugs & Pharmaceuticals (AKUMS) has a market capitalisation of Rs 12,939.36 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Akums Drugs & Pharmaceuticals
- Akums Drugs & Pharmaceuticals Share Price Fall Streak is in a second straight session, and the cumulative drop now stands at -9.44% from Rs 822.1.
- The latest traded price of Rs 744.5 is below the previous close of Rs 785.95, keeping Akums Drugs & Pharmaceuticals share price under immediate watch.
- P/E of 42.4 and P/B of 3.62 still frame the valuation after the decline, so the streak has not removed the fundamentals lens.
- ROE of 8.06% and ROCE of 14.77% give investors a direct profitability comparison within the healthcare sector.
- The company remains a Mid Cap stock with a market capitalisation of Rs 12,939.36 crore, which matters for any Akums Drugs & Pharmaceuticals stock analysis.
About Akums Drugs & Pharmaceuticals
Akums Drugs & Pharmaceuticals operates in Healthcare and the Pharmaceuticals & Drugs industry. It is best understood here as a drug and pharmaceutical business whose share price is being judged through a two-session fall streak, valuation multiples and sector positioning. For this article lens, the company matters because the streak is happening while its earnings base, book value and return ratios remain the reference points for interpretation.
That is why Akums Drugs & Pharmaceuticals share price cannot be read only as an intraday figure. The business context, together with its market capitalisation and healthcare peer set, helps readers place the decline in a broader stock analysis frame. Univest data keeps the focus on that factual interpretation rather than on speculation.
Track Akums Drugs & Pharmaceuticals Share Price on Univest
Use Akums Drugs & Pharmaceuticals (AKUMS) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
You can track Akums Drugs & Pharmaceuticals share price on Univest for the latest traded price, fundamental ratios, 52-week levels and market insights. The same page also helps readers compare Akums Drugs & Pharmaceuticals Share Price Fall Streak with sector benchmarks, peer valuation and company financial ratios in one place.
For ongoing stock analysis, Univest makes it easier to follow price moves, valuation context and market-cap details without losing the streak perspective. That is useful when Akums Drugs & Pharmaceuticals share price today needs to be read alongside its fundamentals and its position in Healthcare.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why is Akums Drugs & Pharmaceuticals share price falling today?
Ans. According to Univest data, the latest trade is lower at Rs 744.5 after a 5.27% decline. The price event is confirmed, but no company-specific catalyst is established, so the read stays to the observed move.
What is Akums Drugs & Pharmaceuticals Share Price Fall Streak?
Ans. It refers to the second straight session of decline. Across the two-session run, Akums Drugs & Pharmaceuticals share price has fallen 9.44% from the streak-start base price of Rs 822.1.
What is Akums Drugs & Pharmaceuticals share price today?
Ans. Akums Drugs & Pharmaceuticals share price was Rs 744.5 at the latest trade. That compares with the previous close of Rs 785.95 and reflects a fall of Rs 41.45, or 5.27%, in the current session.
What does the latest price range show?
Ans. The stock opened at Rs 783.35, touched a high of Rs 790 and a low of Rs 740.75. The latest traded price sat much closer to the day’s low, which is the most relevant intraday placement from the session.
How does Akums Drugs & Pharmaceuticals look on valuation?
Ans. The company’s P/E is 42.4 and its P/B is 3.62. In the current streak lens, those ratios sit on a lower price base than before, while earnings per share remain Rs 18.53 and book value remains Rs 216.98.
How does the stock compare with the healthcare benchmark?
Ans. In the same-industry benchmark of 199 companies, the company’s P/E is above the median of 31.28 and below the average of 47.09. Its ROCE of 14.77% is also above both the median and average benchmark levels.
How does Akums Drugs & Pharmaceuticals compare with peers?
Ans. The company’s market cap of Rs 12,939.36 crore is below larger peers such as Sun Pharmaceutical, Divi's Laboratories and Torrent Pharmaceuticals. Its P/E is also below some richer valuations but above more moderate peers like Zydus Lifesciences.
What do EPS, book value and dividend yield show here?
Ans. EPS is Rs 18.53, book value is Rs 216.98 and dividend yield is 0.38%. These three figures help frame the current Akums Drugs & Pharmaceuticals share price against earnings, accounting net worth and payout history.
Should investors track Akums Drugs & Pharmaceuticals on Univest?
Ans. Yes, if they want to follow Akums Drugs & Pharmaceuticals share price with valuation ratios, market capitalisation, 52-week levels and sector context in one place. Univest keeps the price action and fundamentals aligned for quick comparison.
